Clinical Trial Update: L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 study of L-778,123 in patients with recurrent or refractory solid tumors, including head and neck cancer, has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• L-778,123

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Head and Neck Cancer, Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Status: COMPLETED